BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ChemRar Ventures and Sanofi (France) (SAN.PA)Sign a Scouting Pharma Partnering Agreement


5/2/2013 11:51:31 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MOSCOW--(Marketwired - May 02, 2013) - ChemRar Ventures announced during BIO Convention in Chicago that the scouting agreement for a venture investment in Russia and Asia was signed between ChemRar Ventures and Sanofi. The Agreement envisages that ChemRar Ventures will be sourcing early and late stage compounds within a certain defined area of Sanofi's therapeutic interest and negotiating the potential pharma partnering engagement with Sanofi.

The agreement is signed for 18 months and may be extended thereafter. With over 20 years of experience in research in Russia ChemRar is well known for its history in designing and developing innovative drugs in a multitude of therapeutic areas. Working in the framework of this scouting agreement ChemRar will partner with a number of academic Institutions including Moscow Institute of Physics and Technology, Petrov's Institute of Oncology, Center of Endocrinology of the Russian Academy of Medical Sciences, UCSD, Scripps Research Institute, Salk Institute, Wi2 of University of Wisconsin, Fox Chase Cancer Center and others.

Nikolay Merkin, CEO at ChemRar Ventures, stated: "We are pleased with Sanofi's decision to look deeper into Russian science, and search for innovation in partnership with Russian Universities and biotechs. We are interested to further expand our joint venture pharma partnering relationships involving both publicly and privately funded organizations. We hope that this is a first step in fostering a platform for true co-investment, co-licensing and co-development collaborations with Sanofi. Those we achieved with other major corporate partners interested in leveraging their business on the high growing pharmaceutical markets."

About ChemRar Ventures
ChemRar Ventures is a Russian venture investment company, managing the diversified portfolio of investments in biopharma, diagnostics and medical device companies in high growth markets of Russia, EurAsEc and Eastern Europe.

About ChemRar HTC
ChemRar High Tech Center, a unique group of biotech, R&D service, manufacturing and venture investment companies developing and commercializing innovative treatments for unmet medical needs, including biopharma products medical devices and diagnostics for cardiometabolic, infectious diseases, oncology, hematology, reproductive health and CNS therapeutic area in Russia and worldwide. www.chemrar.ru


Contact for media:
ChemRar HTC Russia
Elena Surina
Email Contact
(926) 206-78-71



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES